Roger M Phillips

List of Publications by Year in Descending Order

128 papers	3,518 citations	35 h-index	54 g-index
134 ext. papers	3,886 ext. citations	5.5 avg, IF	5.27 L-index

#	Paper	IF	Citations
128	Investigation of the cytotoxicity induced by didocosahexaenoin, an omega 3 derivative, in human prostate carcinoma cell lines.. *Current Research in Pharmacology and Drug Discovery*, **2022**, 3, 100085	3	
127	An Efficient Method for the Isolation of Toxins from Pteridium aquilinum and Evaluation of Ptaquiloside Against Cancer and Non-cancer Cells. *Planta Medica*, **2021**, 87, 892-895	3.1	
126	Self-assembly of an anion receptor with metal-dependent kinase inhibition and potent in vitro anti-cancer properties. *Nature Communications*, **2021**, 12, 3898	17.4	1
125	Bis(bipyridine)ruthenium(II) Ferrocenyl Diketonate Complexes: Exhibiting Nanomolar Potency against Human Cancer Cell Lines. *Chemistry - A European Journal*, **2021**, 27, 3737-3744	4.8	6
124	The Warburg effect as a therapeutic target for bladder cancers and intratumoral heterogeneity in associated molecular targets. *Cancer Science*, **2021**, 112, 3822-3834	6.9	3
123	Glycoconjugated Metallohelices have Improved Nuclear Delivery and Suppress Tumour Growth In Vivo. *Angewandte Chemie - International Edition*, **2020**, 59, 14677-14685	16.4	6
122	Ru, Rh and Ir metal complexes of pyridyl chalcone derivatives: Their potent antibacterial activity, comparable cytotoxicity potency and selectivity to cisplatin. *Polyhedron*, **2020**, 185, 114606	2.7	4
121	In vitro biological evaluation of half-sandwich platinum-group metal complexes containing benzothiazole moiety. *Journal of Coordination Chemistry*, **2020**, 73, 1538-1553	1.6	1
120	Glycoconjugated Metallohelices have Improved Nuclear Delivery and Suppress Tumour Growth In Vivo. *Angewandte Chemie*, **2020**, 132, 14785-14793	3.6	1
119	Silver(I) N-Heterocyclic Carbene Complexes Derived from Clotrimazole: Antiproliferative Activity and Interaction with an Artificial Membrane-Based Biosensor. *Organometallics*, **2020**, 39, 1318-1331	3.8	5
118	Triazole-based, optically-pure metallosupramolecules; highly potent and selective anticancer compounds. *Chemical Communications*, **2020**, 56, 6392-6395	5.8	8
117	Utilization of novel self-nanoemulsifying formulations (SNEFs) loaded paclitaxel for the treatment prosperity of bladder cancer. *Journal of Drug Delivery Science and Technology*, **2020**, 56, 101514	4.5	4
116	Synthesis, structural and in-vitro functional studies of half-sandwich platinum group metal complexes having various bonding modes of benzhydrazone derivative ligands. *Polyhedron*, **2020**, 176, 114293	2.7	8
115	Revisiting Bromohexitols as a Novel Class of Microenvironment-Activated Prodrugs for Cancer Therapy. *ChemMedChem*, **2020**, 15, 228-235	3.7	
114	Synthesis, structure and bonding modes of pyrazine based ligands of Cp*Rh and Cp*Ir complexes: The study of in-vitro cytotoxicity against human cell lines. *Journal of Organometallic Chemistry*, **2019**, 899, 120887	2.3	5
113	Tethered N-Heterocyclic Carbene-Carboranyl Silver Complexes for Cancer Therapy. *Organometallics* , **2019**, 38, 2530-2538	3.8	10
112	Cellular Uptake and Efflux of Palbociclib In Vitro in Single Cell and Spheroid Models. *Journal of Pharmacology and Experimental Therapeutics*, **2019**, 370, 242-251	4.7	5

111	Inactivation of apaziquone by haematuria: implications for the design of phase III clinical trials against non-muscle invasive bladder cancer. *Cancer Chemotherapy and Pharmacology*, **2019**, 83, 1183-1189	3.5	2
110	Anticancer, antifungal and antibacterial potential of bis(β-ketoiminato)ruthenium(II) carbonyl complexes. *Inorganica Chimica Acta*, **2019**, 498, 119025	2.7	4
109	Discovery of selective, antimetastatic and anti-cancer stem cell metallohelices post-assembly modification. *Chemical Science*, **2019**, 10, 8547-8557	9.4	16
108	Selective anti-cancer activity of non-alkylating minor groove binders. *MedChemComm*, **2019**, 10, 1620-1634	3	6
107	Synthesis, characterization and chemosensitivity studies of half-sandwich ruthenium, rhodium and iridium complexes containing κ1(S) and κ2(N,S) aroylthiourea ligands. *Journal of Organometallic Chemistry*, **2019**, 880, 272-280	2.3	17
106	Synthesis, structural and chemosensitivity studies of arene d6 metal complexes having N-phenyl-N′-(pyridyl/pyrimidyl)thiourea derivatives. *Applied Organometallic Chemistry*, **2018**, 32, e4362	3.1	15
105	Cellular pharmacology studies of anticancer agents: recommendations from the EORTC-PAMM group. *Cancer Chemotherapy and Pharmacology*, **2018**, 81, 427-441	3.5	10
104	Polymer encapsulation of anticancer silver-N-heterocyclic carbene complexes.. *RSC Advances*, **2018**, 8, 10474-10477	3.7	4
103	Ruthenium-Containing Linear Helicates and Mesocates with Tuneable p53-Selective Cytotoxicity in Colorectal Cancer Cells. *Angewandte Chemie - International Edition*, **2018**, 57, 9799-9804	16.4	28
102	Ruthenium-Containing Linear Helicates and Mesocates with Tuneable p53-Selective Cytotoxicity in Colorectal Cancer Cells. *Angewandte Chemie*, **2018**, 130, 9947-9952	3.6	13
101	Half-sandwich d 6 metal complexes comprising of 2-substituted-1,8-napthyridine ligands with unexpected bonding modes: Synthesis, structural and anti-cancer studies. *Journal of Organometallic Chemistry*, **2018**, 854, 27-37	2.3	9
100	Neutral and cationic half-sandwich arene d6 metal complexes containing pyridyl and pyrimidyl thiourea ligands with interesting bonding modes: Synthesis, structural and anti-cancer studies. *Applied Organometallic Chemistry*, **2018**, 32, e4476	3.1	13
99	Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity. *Chemistry - A European Journal*, **2017**, 23, 6341-6356	4.8	19
98	Synthesis, Structural and Biological Studies of Some Half-Sandwich d6-Metal Complexes with Pyrimidine-Based Ligands. *ChemistrySelect*, **2017**, 2, 2065-2076	1.8	9
97	Preclinical anti-cancer activity and multiple mechanisms of action of a cationic silver complex bearing N-heterocyclic carbene ligands. *Cancer Letters*, **2017**, 403, 98-107	9.9	37
96	Drug delivery in a tumour cord model: a computational simulation. *Royal Society Open Science*, **2017**, 4, 170014	3.3	7
95	Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer. *Expert Opinion on Drug Metabolism and Toxicology*, **2017**, 13, 783-791	5.5	16
94	Half-sandwich ruthenium, rhodium and iridium complexes featuring oxime ligands: Structural studies and preliminary investigation of in vitro and in vivo anti-tumour activities. *Applied Organometallic Chemistry*, **2017**, 31, e3640	3.1	12

93	Development and characterization of a microfluidic model of the tumour microenvironment. *Scientific Reports*, **2016**, 6, 36086	4.9	67
92	Synthesis, structural, DFT calculations and biological studies of rhodium and iridium complexes containing azine Schiff-base ligands. *Polyhedron*, **2016**, 117, 404-414	2.7	13
91	Increasing anti-cancer activity with longer tether lengths of group 9 Cp* complexes. *Dalton Transactions*, **2016**, 45, 6812-5	4.3	27
90	Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. *Cancer Chemotherapy and Pharmacology*, **2016**, 77, 441-57	3.5	133
89	Cannabinoid pharmacology in cancer research: A new hope for cancer patients?. *European Journal of Pharmacology*, **2016**, 775, 1-14	5.3	45
88	Anticancer metallohelices: nanomolar potency and high selectivity. *Chemical Science*, **2016**, 7, 951-958	9.4	48
87	Diketonate Titanium Compounds Exhibiting High In Vitro Activity and Specific DNA Base Binding. *ChemistrySelect*, **2016**, 1, 6598-6605	1.8	8
86	Neutral and cationic half-sandwich arene ruthenium, Cp*Rh and Cp*Ir oximato and oxime complexes: Synthesis, structural, DFT and biological studies. *Journal of Organometallic Chemistry*, **2016**, 820, 70-81	2.3	15
85	Synthesis and anticancer activity of silver(I)-N-heterocyclic carbene complexes derived from the natural xanthine products caffeine, theophylline and theobromine. *Dalton Transactions*, **2015**, 44, 7563-9	4.3	53
84	Evaluation of novel imidazotetrazine analogues designed to overcome temozolomide resistance and glioblastoma regrowth. *Molecular Cancer Therapeutics*, **2015**, 14, 111-9	6.1	17
83	Hypoxia-Sensitive Metal Ketoiminato Complexes Showing Induced Single-Strand DNA Breaks and Cancer Cell Death by Apoptosis. *Journal of Medicinal Chemistry*, **2015**, 58, 4940-53	8.3	56
82	Synthesis and anticancer activity evaluation of (5)-C5(CH3)4R ruthenium complexes bearing chelating diphosphine ligands. *Dalton Transactions*, **2015**, 44, 3265-70	4.3	7
81	Mathematical and computational models of drug transport in tumours. *Journal of the Royal Society Interface*, **2014**, 11, 20131173	4.1	27
80	Rhodium, iridium, and ruthenium half-sandwich picolinamide complexes as anticancer agents. *Inorganic Chemistry*, **2014**, 53, 727-36	5.1	101
79	NCI in vitro and in silico anticancer screen, cell cycle pertubation and apoptosis-inducing potential of new acylated, benzylidene and isopropylidene derivatives of andrographolide. *Environmental Toxicology and Pharmacology*, **2014**, 38, 489-501	5.8	11
78	Asymmetric triplex metallohelices with high and selective activity against cancer cells. *Nature Chemistry*, **2014**, 6, 797-803	17.6	99
77	In vitro 3D colon tumor penetrability of SRJ09, a new anti-cancer andrographolide analog. *Investigational New Drugs*, **2014**, 32, 806-14	4.3	4
76	Mononuclear half-sandwich cyclic-perimeter platinum group metal complexes having bithiazole ligands: Synthesis, molecular and anti-cancer studies. *Inorganica Chimica Acta*, **2014**, 421, 349-358	2.7	12

75	Identification of LDH-A as a therapeutic target for cancer cell killing via (i) p53/NAD(H)-dependent and (ii) p53-independent pathways. *Oncogenesis*, **2014**, 3, e102	6.6	75
74	Hypoxia modulates the activity of a series of clinically approved tyrosine kinase inhibitors. *British Journal of Pharmacology*, **2014**, 171, 224-36	8.6	22
73	Mechanistic and cytotoxicity studies of group IV Ediketonate complexes. *ChemMedChem*, **2014**, 9, 1136-9	3.7	18
72	Synthesis and quantitative structure-activity relationship of imidazotetrazine prodrugs with activity independent of O6-methylguanine-DNA-methyltransferase, DNA mismatch repair, and p53. *Journal of Medicinal Chemistry*, **2013**, 56, 7120-32	8.3	10
71	Carbophilic 3-component cascades: access to complex bioactive cyclopropyl diindolylmethanes. *Chemistry - A European Journal*, **2013**, 19, 2180-4	4.8	22
70	Imatinib radiosensitizes bladder cancer by targeting homologous recombination. *Cancer Research*, **2013**, 73, 1611-20	10.1	29
69	Metallohelices with activity against cisplatin-resistant cancer cells; does the mechanism involve DNA binding?. *Chemical Science*, **2013**, 4, 4407	9.4	52
68	Multi-objective multi-drug scheduling schemes for cell cycle specific cancer treatment. *Computers and Chemical Engineering*, **2013**, 58, 14-32	4	14
67	EO9 (Apaziquone): from the clinic to the laboratory and back again. *British Journal of Pharmacology*, **2013**, 168, 11-8	8.6	56
66	Measles virus causes immunogenic cell death in human melanoma. *Gene Therapy*, **2013**, 20, 7-15	4	120
65	Minor structural modifications to alchemix influence mechanism of action and pharmacological activity. *Biochemical Pharmacology*, **2012**, 83, 1514-22	6	4
64	Avascular tumour growth dynamics and the constraints of protein binding for drug transportation. *Journal of Theoretical Biology*, **2012**, 313, 142-52	2.3	13
63	Characterization of changes in the proteome in different regions of 3D multicell tumor spheroids. *Journal of Proteome Research*, **2012**, 11, 2863-75	5.6	51
62	Strategy for Imidazotetrazine Prodrugs with Anticancer Activity Independent of MGMT and MMR. *ACS Medicinal Chemistry Letters*, **2012**, 3, 965-8	4.3	7
61	Enhanced cytotoxicity of silver complexes bearing bidentate N-heterocyclic carbene ligands. *Dalton Transactions*, **2012**, 41, 3720-5	4.3	61
60	Synthesis of iridium and ruthenium complexes with (N,N), (N,O) and (O,O) coordinating bidentate ligands as potential anti-cancer agents. *Dalton Transactions*, **2012**, 41, 13800-2	4.3	71
59	A hybrid cellular automaton model of solid tumor growth and bioreductive drug transport. *IEEE/ACM Transactions on Computational Biology and Bioinformatics*, **2012**, 9, 1595-606	3	11
58	Modelling of Tirapazamine Effects on Solid Tumour Morphology. *Advances in Intelligent and Soft Computing*, **2011**, 125-132		1

57	Intelligent Modelling for Benign Tumour Growth with Cell-Cell and Cell-Matrix Adhesion and Movement **2010**,		3
56	A mathematical model of doxorubicin penetration through multicellular layers. *Journal of Theoretical Biology*, **2009**, 257, 598-608	2.3	19
55	To determine the cytotoxicity of chlorambucil and one of its nitro-derivatives, conjugated to prasterone and pregnenolone, towards eight human cancer cell-lines. *European Journal of Medicinal Chemistry*, **2009**, 44, 2944-51	6.8	17
54	Response of multiple recurrent TaT1 bladder cancer to intravesical apaziquone (EO9): comparative analysis of tumor recurrence rates. *Urology*, **2009**, 73, 1083-6	1.6	35
53	Hypoxia-selective targeting by the bioreductive prodrug AQ4N in patients with solid tumors: results of a phase I study. *Clinical Cancer Research*, **2008**, 14, 1096-104	12.9	86
52	A Cytotoxic Diterpenoid from Croton Membranaceus, the Major Constituent of Anticancer Herbal Formulations Used in Ghana. *Natural Product Communications*, **2008**, 3, 1934578X0800301	0.9	3
51	Glut-1 as a therapeutic target: increased chemoresistance and HIF-1-independent link with cell turnover is revealed through COMPARE analysis and metabolomic studies. *Cancer Chemotherapy and Pharmacology*, **2008**, 61, 377-93	3.5	63
50	Synthesis of cryptolepine analogues as potential bioreducible anticancer agents. *Bioorganic and Medicinal Chemistry*, **2007**, 15, 6353-60	3.4	18
49	Chemical synthesis and biological evaluation of a NAD(P)H:quinone oxidoreductase-1 targeted tripartite quinone drug delivery system. *Molecular Cancer Therapeutics*, **2007**, 6, 3122-30	6.1	34
48	Tailoring targeted therapy to individual patients: lessons to be learnt from the development of mitomycin C. *Cancer Genomics and Proteomics*, **2007**, 4, 175-86	3.3	5
47	Methionine dependence of tumours: a biochemical strategy for optimizing paclitaxel chemosensitivity in vitro. *Biochemical Pharmacology*, **2006**, 71, 772-8	6	19
46	Phase I/II pilot study of intravesical apaziquone (EO9) for superficial bladder cancer. *Journal of Urology*, **2006**, 176, 1344-8	2.5	35
45	Formation of DNA interstrand cross-links as a marker of Mitomycin C bioreductive activation and chemosensitivity. *European Journal of Cancer*, **2005**, 41, 1331-8	7.5	20
44	Synthesis of some cryptolepine analogues, assessment of their antimalarial and cytotoxic activities, and consideration of their antimalarial mode of action. *Journal of Medicinal Chemistry*, **2005**, 48, 2701-9	8.3	84
43	Expression of HIF-1alpha and Glut-1 in human bladder cancer. *Oncology Reports*, **2005**, 14, 909-13	3.5	43
42	Intrinsic chemotherapy resistance to the tubulin-binding antimitotic agents in renal cell carcinoma. *International Journal of Cancer*, **2005**, 115, 155-63	7.5	24
41	Biological and Clinical Significance of Polymorphisms in NAD(P)H: Quinone Oxidoreductase 1 (NQO1). *Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics*, **2004**, 2, 75-82		1
40	Comparative efficacy of novel platinum(IV) compounds with established chemotherapeutic drugs in solid tumour models. *Biochemical Pharmacology*, **2004**, 67, 17-30	6	44

39	Analysis of cell-cycle kinetics and sulfur amino acid metabolism in methionine-dependent tumor cell lines; the effect of homocysteine supplementation. *Biochemical Pharmacology*, **2004**, 67, 1587-99	6	19
38	Pharmacological and biological evaluation of a series of substituted 1,4-naphthoquinone bioreductive drugs. *Biochemical Pharmacology*, **2004**, 68, 2107-16	6	37
37	Immunohistochemical analysis of NAD(P)H:quinone oxidoreductase and NADPH cytochrome P450 reductase in human superficial bladder tumours: relationship between tumour enzymology and clinical outcome following intravesical mitomycin C therapy. *International Journal of Cancer*, **2004**, 109, 703-9	7.5	24
36	Detection of (NAD(P)H:Quinone oxidoreductase-1, EC 1.6.99.2) 609C-->T and 465C-->T polymorphisms in formalin-fixed, paraffin-embedded human tumour tissue using PCR-RFLP. *International Journal of Oncology*, **2004**, 24, 1005-10	1	3
35	3-substituted-5-aziridinyl-1-methylindole-4,7-diones as NQO1-directed antitumour agents: mechanism of activation and cytotoxicity in vitro. *Biochemical Pharmacology*, **2003**, 66, 1199-206	6	16
34	Obtaining archived pathological material for biomedical research. *Lancet, The*, **2003**, 361, 1394	40	3
33	Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts. *Molecular Cancer Therapeutics*, **2003**, 2, 901-9	6.1	23
32	Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9. *British Journal of Pharmacology*, **2002**, 137, 701-9	8.6	29
31	In vitro and in vivo activity of LS 4477 and LS 4559, novel analogues of the tubulin binder estramustine. *European Journal of Cancer*, **2002**, 38, 194-204	7.5	23
30	A novel strategy for NQO1 (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) mediated therapy of bladder cancer based on the pharmacological properties of EO9. *British Journal of Cancer*, **2001**, 85, 1137-46	8.7	47
29	Genotyping of NAD(P)H:quinone oxidoreductase (NQO1) in a panel of human tumor xenografts: relationship between genotype status, NQO1 activity and the response of xenografts to Mitomycin C chemotherapy in vivo(1). *Biochemical Pharmacology*, **2001**, 62, 1371-7	6	16
28	Hollow fiber assay for tumor angiogenesis. *Methods in Molecular Medicine*, **2001**, 46, 87-93		2
27	Synthesis and evaluation of cryptolepine analogues for their potential as new antimalarial agents. *Journal of Medicinal Chemistry*, **2001**, 44, 3187-94	8.3	150
26	Molecular Modelling of Human DT-Diaphorase For Enzyme-Directed Bioreductive Drug Design. *Molecular Simulation*, **2000**, 24, 209-214	2	3
25	Pharmacological properties of a new aziridinylbenzoquinone, RH1 (2,5-diaziridinyl-3-(hydroxymethyl)-6-methyl-1,4-benzoquinone), in mice. *Biochemical Pharmacology*, **2000**, 59, 831-7	6	35
24	The relative importance of NADPH: cytochrome c (P450) reductase for determining the sensitivity of human tumour cells to the indolequinone EO9 and related analogues lacking functionality at the C-2 and C-3 positions. *Biochemical Pharmacology*, **2000**, 59, 993-6	6	36
23	Bioreductive activation of a series of indolequinones by human DT-diaphorase: structure-activity relationships. *Journal of Medicinal Chemistry*, **1999**, 42, 4071-80	8.3	58
22	Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development. *Biochemical Pharmacology*, **1999**, 58, 303-10	6	22

21	Evaluation of a novel in vitro assay for assessing drug penetration into avascular regions of tumours. *British Journal of Cancer*, **1998**, 77, 2112-9	8.7	59
20	Prospects for bioreductive drug development. *Expert Opinion on Investigational Drugs*, **1998**, 7, 905-28	5.9	7
19	Characterization of a polymorphism in NAD(P)H: quinone oxidoreductase (DT-diaphorase). *British Journal of Cancer*, **1997**, 75, 69-75	8.7	245
18	Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. *European Journal of Cancer*, **1997**, 33, 1291-8	7.5	56
17	Plateau-phase cultures: an experimental model for identifying drugs which are bioactivated within the microenvironment of solid tumours. *British Journal of Cancer*, **1997**, 75, 196-201	8.7	19
16	Bioreductive activation of a series of analogues of 5-aziridinyl-3-hydroxymethyl-1-methyl-2-[1H-indole-4, 7-dione] prop-beta-en-alpha-ol (EO9) by human DT-diaphorase. *Biochemical Pharmacology*, **1996**, 52, 1711-8	6	42
15	Synthesis and antitumour activity of new derivatives of flavone-8-acetic acid (FAA). Part 1: 6-Methyl derivatives. *Archiv Der Pharmazie*, **1996**, 329, 489-97	4.3	6
14	Synthesis and anti-tumour activity of 6-methyl derivatives of flavone-8-acetic acid (FAA). *Bioorganic and Medicinal Chemistry Letters*, **1994**, 4, 2313-2316	2.9	5
13	Pre-clinical evaluation of a novel chloroethylating agent, Clomesone. *British Journal of Cancer*, **1993**, 67, 441-6	8.7	1
12	In vitro activity of the novel indoloquinone EO-9 and the influence of pH on cytotoxicity. *British Journal of Cancer*, **1992**, 65, 359-64	8.7	56
11	Evaluation of the anti-tumour action and acute toxicity of kosins from Hagenia abyssinica. *Journal of Pharmaceutical and Biomedical Analysis*, **1992**, 10, 555-60	3.5	14
10	Flavone acetic acid: is vascular shutdown the crucial mechanism of action. *International Journal of Radiation Biology*, **1991**, 60, 395-9	2.9	7
9	The relationship between the in vitro chemosensitivity of tumor cells and tumor response in vivo in an experimental tumor model. *International Journal of Cell Cloning*, **1991**, 9, 144-54		4
8	Anti-tumour activity of flavone acetic acid (NSC 347512) in mice--influence of immune status. *British Journal of Cancer*, **1991**, 63, 57-62	8.7	41
7	The relationship between tissue levels of flavone acetic acid (NSC 347512) and site dependent anti-tumour activity in murine colon tumours. *British Journal of Cancer*, **1991**, 63, 541-5	8.7	1
6	A critical appraisal of the predictive value of in vitro chemosensitivity assays. *Journal of the National Cancer Institute*, **1990**, 82, 1457-68	9.7	80
5	Influence of site on the chemosensitivity of transplantable murine colon tumours to flavone acetic acid (LM975, NSC 347512). *Cancer Chemotherapy and Pharmacology*, **1989**, 24, 87-94	3.5	16
4	Experimental correlations of in vitro drug sensitivity with in vivo responses to ThioTEPA in a panel of murine colon tumours. *Cancer Chemotherapy and Pharmacology*, **1988**, 21, 168-72	3.5	13

3	In vitro and in vivo responses of a panel of murine colon tumours to TCNU: a positive correlation. *European Journal of Cancer & Clinical Oncology*, **1988**, 24, 1365-71		4
2	Influence of the tissue distribution of ThioTEPA and its metabolite, TEPA, on the response of murine colon tumours. *Cancer Chemotherapy and Pharmacology*, **1987**, 20, 203-6	3.5	4
1	Factors involved in the anti-cancer activity of the investigational agents LM985 (flavone acetic acid ester) and LM975 (flavone acetic acid). *British Journal of Cancer*, **1987**, 55, 159-63	8.7	50